Elevation Oncology Inc
NASDAQ:ELEV
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Sichuan Anning Iron and Titanium Co Ltd
SZSE:002978
|
CN |
|
R
|
R&G PharmaStudies Co Ltd
SZSE:301333
|
CN |
|
T
|
Telecom Digital Holdings Ltd
HKEX:6033
|
HK |
|
Venky's (India) Ltd
NSE:VENKEYS
|
IN |
|
Wealthy Way Group Ltd
HKEX:3848
|
HK |
|
Poonawalla Fincorp Ltd
NSE:POONAWALLA
|
IN |
Elevation Oncology Inc
Retained Earnings
Elevation Oncology Inc
Retained Earnings Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Retained Earnings | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Elevation Oncology Inc
NASDAQ:ELEV
|
Retained Earnings
-$240.5m
|
CAGR 3-Years
-63%
|
CAGR 5-Years
-110%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Retained Earnings
-$15.5B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Retained Earnings
$13.7B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-3%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Retained Earnings
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Retained Earnings
$13.6B
|
CAGR 3-Years
28%
|
CAGR 5-Years
74%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Retained Earnings
$35.8B
|
CAGR 3-Years
15%
|
CAGR 5-Years
27%
|
CAGR 10-Years
45%
|
|
Elevation Oncology Inc
Glance View
Elevation Oncology, Inc. operates as a precision oncology company. The company is headquartered in New York City, New York and currently employs 35 full-time employees. The company went IPO on 2021-06-25. The firm is focused on the development of targeted therapeutics for the treatment of cancer in genomically-defined patient populations. The company focuses on identifying oncogenic drivers with other driver alterations and in the conduct of clinical trials. Its lead drug development candidate, seribantumab, is an Anti-HER3 monoclonal antibody and potential targeted therapy for solid tumors driven by neuregulin-1 (NRG1) fusions, which are genomic alterations that are identified as oncogenic driver alterations. Its NRG1 is the primary activating ligand of HER3. The firm's clinical trial, CRESTONE, is a Phase II study of seribantumab in cancer patients with a solid tumor of any origin that expresses a genomic change called an NRG1 fusion.
See Also
What is Elevation Oncology Inc's Retained Earnings?
Retained Earnings
-240.5m
USD
Based on the financial report for Dec 31, 2024, Elevation Oncology Inc's Retained Earnings amounts to -240.5m USD.
What is Elevation Oncology Inc's Retained Earnings growth rate?
Retained Earnings CAGR 5Y
-110%
Over the last year, the Retained Earnings growth was -23%. The average annual Retained Earnings growth rates for Elevation Oncology Inc have been -63% over the past three years , -110% over the past five years .
